Pyoderma gangrenosum secondary to chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Dermatology
• Immunotherapy

Background:

• Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis presenting as rapidly progressive, painful ulcers.
• A patient with diffuse large B-cell lymphoma and skin involvement developed PG after CAR T-cell therapy.

Purpose of the Study:

• To report a case of pyoderma gangrenosum developing after CAR T-cell therapy.
• To discuss the management and potential relationship between immunotherapy and cutaneous reactions.

Main Methods:

• A patient with diffuse large B-cell lymphoma received CAR T-cell therapy.
• Subsequent development of pyoderma gangrenosum was observed.
• Treatment involved prednisone taper and wound vacuum therapy.

Main Results:

• The patient's pyoderma gangrenosum showed complete granulation and 90% reepithelialization at 3 months.
• The ulcer fully resolved within 4 months without recurrence.
• Standard PG treatment was effective.

Conclusions:

• The relationship between CAR T-cell therapy and pyoderma gangrenosum is currently unknown.
• Effective management of immunotherapy-induced PG can be achieved with standard treatments.
• Further research is needed to understand the significance of CAR T-cell therapy on post-treatment cutaneous reactions.